Protease Inhibitors

Once-daily Boosted Fosamprenavir or Atazanavir in Treatment-naive Patients: The ALERT Study   10/06/06

Trizivir versus Unboosted Atazanavir/AZT/3TC: The ACTION Study   10/03/06

Liver Toxicity Associated with Ritonavir-boosted Tipranavir   10/03/06

Efficacy and Impact on Lipids of Reduced Lopinavir/ritonavir Dosing   10/03/06

Absence of Sex Differences in Fosamprenavir Efficacy and Safety   9/29/06

The KLEAN Study: 48-week Analysis Demonstrates Non-inferiority and Rare Resistance   9/29/06

96-week RESIST Data Show Boosted Tipranavir Produces Superior and Durable Treatment Response   9/29/06

When Does CD4 Cell Count Plateau? Evidence from Patients Treated with Lopinavir/ritonavir for up to 7 Years   9/29/06






Google_______________



 

 

 

 



 

 

 

 

 


Conference
Main Page